A Phase 1 interventional study of HMI-115 in Androgenetic Alopecia, sponsored by Hope Medicine (Nanjing) Co., Ltd. Completed at 1 site in Australia. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Hope Medicine (Nanjing) Co., Ltd · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Alopecia with a site in Australia — 3 open to participants now, 4 under way, 1 of them phase 3. Alopecia · Australia.
Among the 16 studies in Alopecia with a site in Australia, this one is the 14th largest by enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2022, is one of 3 in phase 1, and was the 9th registered.
512 studies on the registry are indexed under Alopecia; 129 are open to participants now.
Browse Alopecia studies →3 of the 16 studies in Alopecia with a site in Australia are open now. Recruiting first, the newest first:
Olix Pharmaceuticals, Inc. · Sites in Australia, New Zealand
Ages 18–59 · Men only · Healthy volunteers
Absci Pty Ltd. · Sites in Australia
Ages 18–65 · Healthy volunteers
Eli Lilly and Company · Sites in Australia, United States, Argentina and 9 more countries
Ages 6–17
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 75 Alopecia studies recruiting now, 25 (33%) set no upper age limit and 46 (61%) stop at 75 or younger; 9 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 4
First in 2013; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 50 across 431 interventional studies indexed under Alopecia.
Median enrollment 131 across the 14 interventional studies, 300 across the 2 observational. Of the 12 that completed or were terminated, 5 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 16 have an industry lead sponsor. The 10 most frequent:
Hope Medicine (Nanjing) Co., Ltd is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Hope Medicine (Nanjing) Co., Ltd has 2 studies filed under Alopecia — fewer than ten, so there is no comparison to draw.
2 of the studies in Alopecia with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06602232Dren BioA Study of DR-01 in Subjects With Alopecia Areata and Vitiligo | 2027-05 |
| NCT07327359Olix Pharmaceuticals, Inc.A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies in Alopecia with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
An Open Label Study, to Evaluate Safety, Tolerability, and Efficacy Study in Male and Female with Androgenetic Alopecia Treated with HMI-115 over a 24-Week Treatment Period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: HMI-115
Once Every 2 weeks, subcutaneously injection
TAHC(target area hair count) of non-vellus
Change in target area hair count (TAHC) of non-vellus from baseline to Week 24 in male and female AGA subjects, respectively.
Time frame: From baseline to Week 24
TAHC of non-vellus
Change in TAHC of non-vellus from baseline to Week 6, 12, 18, and 36 in male and female, respectively.
Time frame: From baseline to Week 6, 12, 18, and 36
TAHW(target area hair width) of non-vellus hair
Change in target area hair width (TAHW) of non-vellus hair from baseline to Week 6, 12, 18, 24, and 36 in male and female, respectively.
Time frame: From baseline to Week 6, 12, 18, 24, and 36
Investigator Global Assessment (IGA)
IGA at Week 6, 12, 18, 24, and 36 in male and female, respectively.
Time frame: Week 6, 12, 18, 24, and 36
Subject self-Assessment (SSA)
SSA at Week 6, 12, 18, 24, and 36 in male and female, respectively.
Time frame: Week 6, 12, 18, 24, and 36
Hair growth questionnaire assessment (HGQA)
HGQA at Week 6, 12, 18, 24, and 36 in male and female, respectively.
Time frame: Week 6, 12, 18, 24, and 36
Ran from May 2022 to primary completion in Sep 2023, 16 months.
Of 33 phase 1 interventional studies under Alopecia, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 57. This study's 16 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HMI-115
Hope Medicine (Nanjing) Co., Ltd